These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 11451176)

  • 1. Factors influencing ribavirin-induced hemolysis.
    Van Vlierbergh H; Delanghe JR; De Vos M; Leroux-Roel G;
    J Hepatol; 2001 Jun; 34(6):911-6. PubMed ID: 11451176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C.
    Takaki S; Tsubota A; Hosaka T; Akuta N; Someya T; Kobayashi M; Suzuki F; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Gastroenterol; 2004 Jul; 39(7):668-73. PubMed ID: 15293138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.
    Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Hosaka T; Sezaki H; Kobayashi M; Kumada H
    J Gastroenterol; 2004 Nov; 39(11):1090-4. PubMed ID: 15580403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C.
    Oze T; Hiramatsu N; Kurashige N; Tsuda N; Yakushijin T; Kanto T; Takehara T; Kasahara A; Kato M; Yoshihara H; Katayama K; Kubota S; Hijioka T; Ishibashi K; Oshita M; Hagiwara H; Haruna Y; Mita E; Tamura S; Hayashi N
    J Gastroenterol; 2006 Sep; 41(9):862-72. PubMed ID: 17048050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors contributing to ribavirin-induced anemia.
    Nomura H; Tanimoto H; Kajiwara E; Shimono J; Maruyama T; Yamashita N; Nagano M; Higashi M; Mukai T; Matsui Y; Hayashi J; Kashiwagi S; Ishibashi H
    J Gastroenterol Hepatol; 2004 Nov; 19(11):1312-7. PubMed ID: 15482540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increase in platelet count based on inosine triphosphatase genotype during interferon beta plus ribavirin combination therapy.
    Nomura H; Miyagi Y; Tanimoto H; Yamashita N; Ito K; Masaki N; Mizokami M
    J Gastroenterol Hepatol; 2012 Sep; 27(9):1461-6. PubMed ID: 22554247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response.
    Hung CH; Lee CM; Lu SN; Wang JH; Chen CH; Hu TH; Kee KM; Chang KC; Tseng PL; Yen YH; Changchien CS
    Liver Int; 2006 Nov; 26(9):1079-86. PubMed ID: 17032408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ribavirin induced hemolysis: a novel mechanism of action against chronic hepatitis C virus infection.
    Soota K; Maliakkal B
    World J Gastroenterol; 2014 Nov; 20(43):16184-90. PubMed ID: 25473172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-ribavirin treatment in chronic hepatitis C--the less talked about aspects.
    Khalid SR; Khan AA; Alam A; Lak NH; Butt AK; Shafqat F; Alvi A; Ahmed I; Sarwar S; Niazi A
    J Ayub Med Coll Abbottabad; 2009; 21(2):99-102. PubMed ID: 20524481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of nucleoside transporters SLC28A2/3 and SLC29A1/2 genetics in ribavirin therapy: protection against anemia in patients with chronic hepatitis C.
    Doehring A; Hofmann WP; Schlecker C; Zeuzem S; Sarrazin C; Berg T; Müller T; Herrmann E; Geisslinger G; Lötsch J
    Pharmacogenet Genomics; 2011 May; 21(5):289-96. PubMed ID: 21346688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can eicosapentaenoic acid maintain the original ribavirin dose or affect the response during the treatment course of chronic hepatitis C virus (HCV) patients?
    Morsy KH; Zaghloul A; Mahmoud M
    Turk J Gastroenterol; 2016 Jan; 27(1):55-61. PubMed ID: 26674982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?
    Yonem O; Arslan S; Sokmensuer C; Salmanzade S
    Hepatogastroenterology; 2010; 57(99-100):562-6. PubMed ID: 20698227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy.
    Ogawa E; Furusyo N; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
    J Hepatol; 2013 Oct; 59(4):667-74. PubMed ID: 23707372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.
    Liu CH; Huang CF; Liu CJ; Dai CY; Liang CC; Huang JF; Hung PH; Tsai HB; Tsai MK; Chen SI; Lin JW; Yang SS; Su TH; Yang HC; Chen PJ; Chen DS; Chuang WL; Yu ML; Kao JH
    Ann Intern Med; 2013 Dec; 159(11):729-38. PubMed ID: 24297189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of an inosine triphosphate pyrophosphatase genotype on bilirubin increase in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin.
    Tahata Y; Hiramatsu N; Oze T; Morishita N; Harada N; Yamada R; Yakushijin T; Mita E; Hagiwara H; Yamada Y; Ito T; Hijioka T; Inada M; Katayama K; Tamura S; Yoshihara H; Inoue A; Imai Y; Irishio K; Kato M; Hikita H; Sakamori R; Miyagi T; Yoshida Y; Tatsumi T; Hamasaki T; Hayashi N; Takehara T
    J Gastroenterol; 2016 Mar; 51(3):252-9. PubMed ID: 26223482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to avoid discontinuation of ribavirin in combination with interferon to maintain efficacy of treatment for chronic hepatitis C patients.
    Kasahara A
    J Gastroenterol; 2004 Nov; 39(11):1125-6. PubMed ID: 15580413
    [No Abstract]   [Full Text] [Related]  

  • 17. Use of epoetin beta during combination therapy of infection with hepatitis c virus with ribavirin improves a sustained viral response.
    Falasca K; Ucciferri C; Mancino P; Gorgoretti V; Pizzigallo E; Vecchiet J
    J Med Virol; 2010 Jan; 82(1):49-56. PubMed ID: 19950239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ITPA gene polymorphism (94C>A) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C.
    El Raziky M; Zayed NA; Abdel Baki A; Mansour SA; Shahin RMH
    J Med Virol; 2017 Oct; 89(10):1823-1829. PubMed ID: 28480960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between virological response and decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in HCV genotype 1: another story.
    Dai CY; Huang CF; Huang JF; Chuang WL; Yu ML
    Hepatology; 2011 May; 53(5):1774-5; author reply 1775-6. PubMed ID: 21520186
    [No Abstract]   [Full Text] [Related]  

  • 20. Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir.
    Suzuki F; Suzuki Y; Akuta N; Sezaki H; Hirakawa M; Kawamura Y; Hosaka T; Kobayashi M; Saito S; Arase Y; Ikeda K; Kobayashi M; Chayama K; Kamatani N; Nakamura Y; Miyakawa Y; Kumada H
    Hepatology; 2011 Feb; 53(2):415-21. PubMed ID: 21246582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.